Breaking News

ARTES Biotech to Develop VLP SARS-CoV-2 Vax Candidates

Virus-like particles mimic the conformation of authentic native viruses without being infectious.

By: Contract Pharma

Contract Pharma Staff

ARTES Biotechnology, a biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX and SplitCore. METAVAX is a platform for the development of vaccines built on enveloped virus-like particle nanostructures (eVLPs) based on the duck Hepatitis B small surface antigen. SplitCore is the technology where capsid virus-like particles (cVLPs) are applied as...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters